Safety and efficacy of intravenous tenecteplase in patients with acute ischemic stroke in extended time window: systematic review and meta-analysis
Безопасность и эффективность внутривенного введения тенектеплазы у пациентов с острым ишемическим инсультом в расширенном временном окне: систематический обзор и метаанализ
2025-11-29
SCID: 54.1/2rhg9kwr
Discuss with AI
acute ischemic strokeextended time windowintravenous tenecteplasemechanical thrombectomysymptomatic intracranial hemorrhage
Figures from the paper
Abstract (AI)
BACKGROUND: There is limited evidence regarding the safety and efficacy of tenecteplase 0.25 mg/kg in patients with acute ischemic stroke in the extended time window, either with large vessel occlusion or not. Therefore, we aim to assess its safety and efficacy for these patients. METHODOLOGY: We searched PubMed, Scopus, and Web of Science for randomized controlled trials that compared tenecteplase 0.25 mg/kg with the best medical management. Our primary efficacy outcomes included favorable and excellent functional outcomes, measured via the modified Rankin score (mRS), and early neurological improvements. Primary safety outcomes were mortality and symptomatic intracranial hemorrhage rates. Subgroup analyses were performed based on mRs, and the inclusion of patients eligible for mechanical thrombectomy in addition to TNK. RESULTS: Our search found nine randomized controlled trials, of which 8 were included in the meta-analysis. A total of 3068 patients were included. Tenecteplase 0.25 mg/kg did not differ from the control group in achieving excellent functional outcomes and favorable functional outcomes (P values: 0.15 and 0.69), while there was significant improvement in early neurological improvement (P value: 0.02). Symptomatic intracranial hemorrhage was statistically higher in the tenecteplase 0.25 mg/kg group (P value 0.008). Subgroup analyses indicated that patients with mRS 0-1 who receive TNK 0.25 mg/kg do better than those with mRS 0-2. Better results for TNK 0.25 mg/kg were observed in studies that excluded patients eligible for mechanical thrombectomy in addition to TNK. CONCLUSIONS: TNK 0.25 mg/kg appears to significantly achieve early neurological improvement with no effect in achieving excellent or favorable functional outcomes; however, it showed a significant increase in symptomatic intracranial hemorrhage. Patients who performed endovascular thrombectomy after administering TNK 0.25 mg/kg had statistically significantly higher rates of symptomatic intracranial hemorrhage; on the other hand, current evidence endorses the use of tenecteplase 0.25 mg/kg in patients with ischemic strokes whose baseline mRs ranges from 0 to 1. Further RCTs are necessary to validate these findings. Prospero registration number: CRD42025636473.
Key Findings
1
A systematic review identified nine randomized controlled trials, with eight included in meta-analysis, totaling 3,068 patients with acute ischemic stroke in the extended time window.
2
Outcomes were better in studies excluding patients eligible for mechanical thrombectomy in addition to tenecteplase.
3
Patients achieving mRS 0–1 appeared to benefit more from tenecteplase than those achieving mRS 0–2 in subgroup analyses.
4
Tenecteplase 0.25 mg/kg significantly improved early neurological outcomes compared with best medical management, but did not improve excellent or favorable functional outcomes.
5
Tenecteplase 0.25 mg/kg was associated with a statistically significant increase in symptomatic intracranial hemorrhage.
Research Object
Intravenous tenecteplase 0.25 mg/kg treatment in patients with acute ischemic stroke in the extended time window
Research Subject
Safety and efficacy, including functional outcomes, early neurological improvement, mortality, and symptomatic intracranial hemorrhage
Publication Details
Publication Date
2025-11-29
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest